Ki Cheong Park

1.3k total citations
36 papers, 666 citations indexed

About

Ki Cheong Park is a scholar working on Oncology, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Ki Cheong Park has authored 36 papers receiving a total of 666 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Molecular Biology and 11 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Ki Cheong Park's work include Thyroid Cancer Diagnosis and Treatment (11 papers), Cancer-related Molecular Pathways (10 papers) and Endoplasmic Reticulum Stress and Disease (6 papers). Ki Cheong Park is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (11 papers), Cancer-related Molecular Pathways (10 papers) and Endoplasmic Reticulum Stress and Disease (6 papers). Ki Cheong Park collaborates with scholars based in South Korea, United States and Canada. Ki Cheong Park's co-authors include Seung Won Kim, Seung Hoon Choi, Jeong Yong Jeon, Hang‐Seok Chang, Seok‐Mo Kim, Jae‐Ho Cheong, Ho Jeong Kwon, Soo Young Kim, Sang Yong Kim and Tae Il Kim and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Clinical Cancer Research.

In The Last Decade

Ki Cheong Park

35 papers receiving 658 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ki Cheong Park South Korea	16	360	190	114	113	97	36	666
Dongwei Jia China	15	344 1.0×	124 0.7×	136 1.2×	133 1.2×	30 0.3×	23	584
Xundi Xu China	13	424 1.2×	130 0.7×	206 1.8×	63 0.6×	39 0.4×	31	718
Yufeng Hu China	19	541 1.5×	126 0.7×	234 2.1×	172 1.5×	39 0.4×	36	910
Yan‐Jiun Huang Taiwan	17	354 1.0×	226 1.2×	135 1.2×	68 0.6×	54 0.6×	48	901
Lei Gong China	15	378 1.1×	158 0.8×	129 1.1×	70 0.6×	29 0.3×	45	700
Yan–Xin Chang China	12	355 1.0×	81 0.4×	211 1.9×	288 2.5×	67 0.7×	17	820
Wang‐Xiang Xu China	12	475 1.3×	83 0.4×	111 1.0×	122 1.1×	31 0.3×	23	755
Aida S. Hansen Denmark	10	509 1.4×	247 1.3×	184 1.6×	81 0.7×	42 0.4×	21	903
Manoj Amrutkar Norway	18	445 1.2×	421 2.2×	218 1.9×	249 2.2×	86 0.9×	31	1.0k
Guiyu Lou China	15	630 1.8×	308 1.6×	339 3.0×	190 1.7×	51 0.5×	33	1.1k

Countries citing papers authored by Ki Cheong Park

Since Specialization

Citations

This map shows the geographic impact of Ki Cheong Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ki Cheong Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ki Cheong Park more than expected).

Fields of papers citing papers by Ki Cheong Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ki Cheong Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ki Cheong Park. The network helps show where Ki Cheong Park may publish in the future.

Co-authorship network of co-authors of Ki Cheong Park

This figure shows the co-authorship network connecting the top 25 collaborators of Ki Cheong Park. A scholar is included among the top collaborators of Ki Cheong Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ki Cheong Park. Ki Cheong Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Seok‐Mo, Keunwan Park, Keunwan Park, et al.. (2025). Identification of new small molecules for selective inhibition of SERCA 1 in patient‐derived metastatic papillary thyroid cancer. British Journal of Pharmacology. 182(11). 2392–2408. 2 indexed citations

Park, Ki Cheong, Jeong‐Ki Min, Sang Yong Kim, et al.. (2023). PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models. BMC Medicine. 21(1). 38–38. 11 indexed citations

Kim, Minki, Sang Yong Kim, Sungsoon Fang, et al.. (2022). Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer. International Journal of Molecular Sciences. 23(2). 699–699. 11 indexed citations

Woo, Hyun, Jeong‐Ki Min, Da Hye Kim, et al.. (2022). Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer. Cancer Gene Therapy. 30(5). 694–703. 3 indexed citations

Lim, Jin Hong, Sang-Yong Kim, Sang-Yong Kim, et al.. (2022). Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model. Biomedicines. 10(8). 1901–1901. 2 indexed citations

Kim, Hee Jun, Jungmin Kim, Sang Yong Kim, et al.. (2021). Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models. International Journal of Molecular Sciences. 22(2). 536–536. 8 indexed citations

Kim, Da Hye, Soochan Kim, Soochan Kim, et al.. (2020). Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice. International Journal of Medical Microbiology. 310(2). 151391–151391. 39 indexed citations

Lim, Jin Hong, et al.. (2020). Patient-Derived, Drug-Resistant Colon Cancer Cells Evade Chemotherapeutic Drug Effects via the Induction of Epithelial-Mesenchymal Transition-Mediated Angiogenesis. International Journal of Molecular Sciences. 21(20). 7469–7469. 7 indexed citations

Pak, Kyung Ho, Ki Cheong Park, & Jae‐Ho Cheong. (2019). VEGF-C induced by TGF- β1 signaling in gastric cancer enhances tumor-induced lymphangiogenesis. BMC Cancer. 19(1). 799–799. 37 indexed citations

10.

Kim, Soo Young, Seok‐Mo Kim, Bup‐Woo Kim, et al.. (2018). SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer. BMC Cancer. 18(1). 956–956. 21 indexed citations

11.

Park, Ki Cheong, Seung Won Kim, Jeong Yong Jeon, et al.. (2017). Survival of Cancer Stem-Like Cells Under Metabolic Stress via CaMK2α-mediated Upregulation of Sarco/Endoplasmic Reticulum Calcium ATPase Expression. Clinical Cancer Research. 24(7). 1677–1690. 34 indexed citations

12.

Park, Ki Cheong, Seok‐Mo Kim, Jeong Yong Jeon, et al.. (2017). Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer. Neoplasia. 19(3). 145–153. 16 indexed citations

13.

Han, Kyung Seok, Na Li, Ladan Fazli, et al.. (2015). Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2α pathway. Oncotarget. 6(33). 34818–34830. 16 indexed citations

14.

Heo, Jun, Ki Cheong Park, Kang Su Cho, Sung Joon Hong, & Kyung Seok Han. (2015). Abstract 1322: Expression of programmed cell death ligand 1/2 and BCG immunotherapy in bladder cancer. Cancer Research. 75(15_Supplement). 1322–1322. 1 indexed citations

15.

Kim, Seok‐Mo, Ki Cheong Park, Jeong Yong Jeon, et al.. (2015). Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer. BMC Cancer. 15(1). 1003–1003. 20 indexed citations

16.

Jeon, Jeong Yong, Seung Won Kim, Ki Cheong Park, & Mijin Yun. (2015). The bifunctional autophagic flux by 2-deoxyglucose to control survival or growth of prostate cancer cells. BMC Cancer. 15(1). 623–623. 19 indexed citations

17.

Park, Ki Cheong, Ji Hyun Park, Jeong Yong Jeon, et al.. (2014). A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells. British Journal of Pharmacology. 171(21). 4820–4830. 52 indexed citations

18.

Park, Ki Cheong & Seung Hoon Choi. (2013). Effects of endostatin and a new drug terpestacin against human neuroblastoma xenograft and cell lines. Pediatric Surgery International. 29(12). 1327–1340. 7 indexed citations

19.

Jung, Hye Jin, Joong Sup Shim, Jiyong Lee, et al.. (2010). Terpestacin Inhibits Tumor Angiogenesis by Targeting UQCRB of Mitochondrial Complex III and Suppressing Hypoxia-induced Reactive Oxygen Species Production and Cellular Oxygen Sensing. Journal of Biological Chemistry. 285(15). 11584–11595. 101 indexed citations

20.

Park, Ki Cheong, et al.. (2008). Effect of selective cyclooxygenase‐2 inhibitor meloxicam on liver fibrosis in rats with ligated common bile ducts. Hepatology Research. 38(8). 800–809. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact